Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
A major challenge for the application of peptide therapeutics is their short half-lifein vivo. Here, the authors design peptide-fatty acid chimeras bearing an engineered linker that promotes albumin binding and allows longer circulation times of therapeutic peptides in animal models.
Main Authors: | Alessandro Zorzi, Simon J. Middendorp, Jonas Wilbs, Kaycie Deyle, Christian Heinis |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms16092 |
Similar Items
-
Modified heptapeptide from tau binds both tubulin and microtubules
by: Jingrui Li, et al.
Published: (2020-10-01) -
Identification and Characterization of Novel Fc-Binding Heptapeptides from Experiments and Simulations
by: Xiaoquan Sun, et al.
Published: (2018-07-01) -
Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
by: Jonas Wilbs, et al.
Published: (2020-08-01) -
Conformational Ensembles by NMR and MD Simulations in Model Heptapeptides with Select Tri-Peptide Motifs
by: V. V. Krishnan, et al.
Published: (2021-01-01) -
Development of Protein-Catalyzed Capture (PCC) Agents with Application to the Specific Targeting of the E17K Point Mutation of AKt1
by: Deyle, Kaycie Marie
Published: (2014)